Table 2.
Experimental Groups, Group Size, and Administered Treatments
Name of the Group | Group Sizea | Administered Treatment |
---|---|---|
NC | 72 | Zebrafish with no xenotransplantation and no SARS-CoV-2 induction |
XMC | 72 | Zebrafish transplanted with human alveolar epithelial A549 cells on the posterior lobe of swim bladder |
DC | 72 | XMC injected with SARS-CoV-2 recombinant S-protein |
1X-Dexa-HED | 72 | DC administered with 0.08 µg/kg body weight of dexamethasone through feed |
0.2X-HED | 72 | DC administered with 6 µg/kg body weight of WiNeWsE through feed |
1X-HED | 72 | DC administered with 28 µg/kg body weight of WiNeWsE through feed |
5X-HED | 72 | DC administered with 142 µg/kg body weight of WiNeWsE through feed |
Notes: aThere were 24 subjects/group/endpoint. There were three endpoints in this study.
Abbreviations: NC, normal control; XMC, xenotransplant model control; DC, disease control; 1X-Dexa-HED, human equivalent dose of dexamethasone; WiNeWsE, withanone enriched Withania somnifera extract; 0.2X-HED, 0.2X human equivalent dose of WiNeWsE; 1X-HED, human equivalent dose of WiNeWsE; 5X-HED, 5X human equivalent dose of WiNeWsE.